Find comprehensive information on Leiomyosarcoma diagnosis, including ICD-10 codes (C49), clinical documentation requirements, histology, immunohistochemistry, treatment options, prognosis, and differential diagnosis. Learn about the latest research, best practices for healthcare professionals, and resources for patients facing this soft tissue sarcoma. This resource covers leiomyosarcoma of the uterus, retroperitoneum, and other sites, focusing on accurate medical coding and optimal patient care.
Also known as
Leiomyosarcoma of uterus
Malignant smooth muscle tumor of the uterus.
Leiomyosarcoma of other female genital organs
Malignant smooth muscle tumor of female organs besides the uterus.
Leiomyosarcoma of retroperitoneum and abdomen
Malignant smooth muscle tumor in the abdominal cavity.
Leiomyosarcoma of other and unspecified sites
Malignant smooth muscle tumor in locations not otherwise specified.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is the leiomyosarcoma specified as of the uterus?
When to use each related code
| Description |
|---|
| Leiomyosarcoma: Smooth muscle cancer |
| Leiomyoma: Smooth muscle tumor |
| Stromal Sarcoma: Connective tissue cancer |
Coding leiomyosarcoma requires precise site identification. Lack of documentation specifying primary site can lead to coding errors and claim denials. Relevant for ICD-10 coding accuracy and CDI.
Leiomyosarcoma diagnosis needs histologic confirmation. Coding without documented pathology report poses an audit risk. Important for healthcare compliance and accurate cancer registry data.
Accurate coding for grade and stage impacts reimbursement and treatment planning. Missing or incorrect documentation of these elements is a common coding and audit risk in leiomyosarcoma cases. Impacts medical coding and CDI.
Patient presents with complaints suggestive of leiomyosarcoma. Presenting symptoms include [specific symptoms e.g., abdominal pain, palpable mass, pelvic pressure, abnormal vaginal bleeding, fatigue, weight loss]. Physical examination revealed [specific findings e.g., palpable abdominal or pelvic mass, tenderness, organomegaly]. Differential diagnosis includes uterine fibroids, other soft tissue sarcomas, gastrointestinal stromal tumors (GIST), and benign smooth muscle tumors. Imaging studies including [specify type e.g., CT scan of the abdomen and pelvis, MRI, ultrasound] were ordered to evaluate the suspected leiomyosarcoma and assess the extent of the disease. Biopsy of the [location of biopsy e.g., uterine mass, retroperitoneal mass] was performed and histopathological analysis confirmed the diagnosis of leiomyosarcoma, demonstrating [specific histologic findings e.g., spindle cell proliferation, mitotic activity, nuclear atypia]. Immunohistochemistry staining was performed, and results were [specify results]. The patient's case was discussed at the multidisciplinary tumor board. Based on the clinical presentation, imaging findings, and pathology report, the patient is diagnosed with leiomyosarcoma, grade [specify grade if available] of the [specify location e.g., uterus, retroperitoneum, extremities]. Treatment options including surgery, chemotherapy, radiation therapy, and targeted therapy were discussed with the patient. The patient elected to proceed with [specified treatment plan]. Patient education regarding leiomyosarcoma prognosis, potential complications, and follow-up care was provided. Referral to [specify specialist e.g., medical oncologist, surgical oncologist, radiation oncologist] was made. The patient will be closely monitored for treatment response and recurrence. ICD-10 code C49.0 (malignant neoplasm of connective and soft tissue of uterus) or appropriate C49 code based on the primary site of the leiomyosarcoma, and appropriate CPT codes for the procedures performed, will be used for billing and coding purposes.